t2d

DMG-PEG 2000 (DMG-PEG2000) can be used for the preparation of lipid nanoparticles for the in vivo delivery of plasmid DNA via oral administration, enhancing the mucosal permeability and delivery efficiency of the nanoparticles. DMG-PEG 2000 can be used for the preparation of liposomes for siRNA transfection, improving transfection efficiency.

Vincamine (Perval) is a major alkaloid of Vinca minor L., Apocynaceae. It has been used therapeutically as a vasodilator and antihypertensive agent, particularly in cerebrovascular disorders.

Retagliptin Phosphate (SP 2086) is pharmaceutical composition of DPP-4 inhibitor, for treating type-2 diabetes.

GSK256073 is an orally active GPR109A agonist. GSK256073 also is a long-lasting and non-flushing HCA2 (hydroxy-carboxylic acid receptor 2) full agonist (pEC50: 7.5). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis.

PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC that acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC50s > 100 μM)[1].

THR-β agonist 2 diacetate (Compound 3) is a potent THR-β agonist with potential applications in researching metabolic disorders such as obesity, hyperlipidemia, hypercholesterolemia, and diabetes, as well as other conditions like steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis, and other related diseases and conditions.

PROTACSirt2 Degrader-2 is a potent and selective PROTAC degrader that targets SIRT2. It exhibits strong antiproliferative activity both in vitro and in vivo. This compound significantly enhances H4K16Ac levels and effectively inhibits colony formation and migration, induces cell cycle arrest, and promotes apoptosis. By indirectly degrading SIRT2 and blocking downstream protein phosphorylation, PROTACSirt2 Degrader-2 disrupts the AKT/mTOR signaling pathway, impeding signaling cascades and inhibiting tumor progression. This compound is used in ovarian cancer research.

Emapunil (XBD-173) is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO.

GSK1292263 is a GPR119 agonist and has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.

Tau Peptide (275-305), also known as the R2 domain fragment, represents the second repeat unit of the microtubule-binding domain of the Alzheimer's tau peptide. Tau Peptide (275-305) is considered crucial in determining the biochemical characteristics of the complete tau protein.

Metofenazate difumarate is a selective calmodulin inhibitor.

XM 323 is an inhibitor of clinical isolates of HIV-1 in vitro and represents a novel class of non-peptidyl inhibitors of HIV-1 protease.

DOOT-2d is a selective MAO-B inhibitor.

AMG131 (CHS 131) , is a novel, non-thiazolidinedione (TZD), selective peroxisome proliferator-activated receptor (PPAR)gamma modulator, which can be used for the treatment of type 2 diabetes mellitus (non-insulin dependent diabetes)

AZD9977 is a novel, selective modulator of mineralocorticoid receptor .

Trelagliptin succinate (SYR-472 succinate) is a long-acting inhibitor of dipeptidyl peptidase-4 (DPP-4), being developed for the treatment of type 2 diabetes (T2D).

BLINK15 is a blood-brain barrier-permeable Cdk5 inhibitor. It reduces CDK5 activity in CDK5/p35 (IC50= 29.34 nM) and CDK5/p25 (IC50= 12.08 nM) complexes. Additionally, BLINK15 exhibits antidiabetic and neuroprotective effects. It lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive abilities, and diminishes neurodegenerative lesions.

BLINK11 is a blood-brain barrier-permeable inhibitor of Cdk5. It reduces the activity of CDK5 by targeting CDK5/p35 (IC50 = 17.09 nM) and CDK5/p25 (IC50 = 14.69 nM) complexes. BLINK11 exhibits antidiabetic and neuroprotective properties, lowers blood glucose levels in type 2 diabetes (T2D) mice, enhances cognitive function, and reduces neurodegenerative lesions.

PSSI-51 is an orally active inhibitor of succinyl-CoA:3-ketoacid CoA transferase (SCOT) with selectivity for peripheral tissues. It effectively inhibits SCOT activity in peripheral tissues such as muscle and kidney, without affecting SCOT activity in brain tissue. By inhibiting SCOT, PSSI-51 reduces ketone body oxidation, thereby improving obesity-related hyperglycemia. It shows potential for research in type 2 diabetes (T2D) and in addressing obesity-related metabolic disorders.

β2AR agonist 2 (compound 8a) is an agonist of the β2-adrenergic receptor (β2AR). It is a saturated azacyclic compound featuring a 4- to 7-membered heterocycle. The compound has a chiral structure in the -R form by incorporating a carbon with a requisite hydroxyl group, which significantly stimulates glucose uptake in skeletal muscle cells, thereby enhancing cellular glucose uptake (GU). β2AR agonist 2 is applicable in the study of type 2 diabetes (T2D).

Cofrogliptin (HSK7653) is an orally available dipeptidyl peptidase-4 (DPP-4) inhibitor with hypoglycemic effects, which can be used to study type 2 diabetes (T2D).

Albiglutide TFA, a glucagon-like peptide (GLP)-1 mimetic, is a long acting GLP-1 receptor agonist. Albiglutide TFA significantly reduces glycosylated hemoglobin (A1C). Albiglutide TFA can be used for type 2 diabetes (T2D) research. Albiglutide TFA is generated by the genetic fusion of a DPP-4-resistant GLP-1 dimer to human albumin [1] [2] [3] .

Dulaglutide (LY2189265) is a GLP-1 receptor agonist for studying type 2 diabetes mellitus (T2DM).

Mazdutide (IBI-362; LY-3305677), a synthetic oxyntomodulin analog, serves as a glucagon-like peptide-1 (GLP-1R)/glucagon receptor (GCGR) co-agonist. Demonstrating safety and tolerability, Mazdutide is utilized in obesity and type 2 diabetes (T2D) research [1] [2].